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ABSTRACT 
OBJECTIVE: Cardiovascular disease is one of the most important causes of 
death in acromegalic patients. The aim of this study is to compare the 
presence of cardiovascular risk factors between acromegalic patients and a 
control population and evaluate the impact of disease control in these factors. 
DESIGN: 11 acromegalic patients with active disease and 12 controlled were 
evaluated for blood pressure, body mass index, fasting glucose, coagulation 
status and lipidic profile. A group of 11 subjects with non-functioning pituitary 
adenoma was used as control population. 
RESULTS: Significant differences were found in lipidic profile, glucose and 
coagulation status in both active and controlled patients. Higher levels of 
fasting glucose and fibrinogen were present in both acromegalic groups. 
Active patients had higher levels of antithrombin III and controlled ones higher 
levels of high density lipoprotein cholesterol, compared with controls. 
Differences between active and controlled acromegalic patients consist in 
reduction of total cholesterol, low density lipoprotein cholesterol and 
antithrombin III in the last. 
CONCLUSIONS: There is some reduction in cardiovascular risk factors with 
control of the disease, but possibly without return to basal levels. 
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Introduction 
Acromegaly is a disease resulting of Growth Hormone (GH) excess 
production.  It is a rare disorder, with an estimated annual incidence of 3 to 4 
cases per million inhabitants per year and a prevalence of 40 to 70 cases per 
million.1 In Portugal, acromegaly’s prevalence and incidence are, respectively, 
56.5 cases per million inhabitants and 2.9 cases per million inhabitants per 
year.2 The mean age at diagnosis is 44 years, after mean symptom duration 
of 8 years.  It seems to affect men and women equally.1  
In more than 90% of cases, acromegaly is caused by a monoclonal benign 
pituitary tumor3 (adenoma – figure 1). GH overproduction will be responsible 
for the stimulation of hepatic production of insulin-like growth factor 1 (IGF-1) 
and, elevated levels of both hormones will cause a number of systemic 
manifestations. Patients usually present with frontal bossing, enlarged nose 
and lips, prognathism, increased interdental space, oily skin, deep voice and 
acral enlargement.3 Increased sweating, joint manifestations, carpal tunnel 
syndrome, visual changes, headache, colon polyps, sleep apnea and 
reproductive, metabolic and cardiovascular disorders can also be present.4 
Diagnosis is based on clinical presentation and levels of fasting or random 
GH and IGF-1. It is excluded when random GH level is lower than 0.4 µg/L 
and IGF-1 level is within the age and sex adjusted normal range. If one of 
these values is altered, an oral 75 g glucose load (OGTT – Oral Glucose 
Tolerance Test) is taken. To rule out acromegaly, the GH level should fall to 1 
µg/L or less.5 
The primary treatment of acromegaly is pituitary surgery. Medical therapy 
can be used after unsuccessful surgery, when the tumor is nonresectable or 
there are important comorbidities, and while awaiting the effectiveness of 
radiation therapy. Radiotherapy is left as a last resort, when the tumor 
continues to grow and is not responsive to medical treatment or when the 
patient has an aggressive tumor with invasion of local structures.4 Cure is 
achieved when IGF-1 levels are in the age and sex adjusted normal range 
and GH level after OGTT is lower than 1 µg/L.5 
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Acromegaly is associated with increased mortality when compared with 
age-matched control population. Cardiovascular, cerebral, cancerous and 
respiratory disorders are considered to be the main causes of death in 
acromegaly, being cardiovascular disease the most important one (around 
40%). 1, 6 High levels of GH/IGF-1 are associated with increased cardiac mass 
and diastolic dysfunction, which is followed by systolic dysfunction in long 
course disease.7, 8 There is also an increase of cardiovascular risk factors in 
acromegaly. In different studies, the prevalence of hypertension ranges from 
18 to 60%.6, 9-12 It is related and involved in worsening of acromegalic 
cardiomyopathy13 and an independent mortality predictor in acromegaly.14 
The prevalence of impaired glucose tolerance in patients with acromegaly 
is estimated to be between 16 and 46%.15 Diabetes Mellitus is present in 19 
to 56% of acromegalic patients, a higher prevalence than among general 
population.15, 16 Abnormalities of glucose metabolism are also significantly 
correlated with increase in blood pressure in this disease.17 
Although there is evidence of an abnormal lipid profile in active 
acromegalic patients, there is some controversy when trying to determine 
which values are changed. Total cholesterol (TC) appears unchanged 
compared with normal population18-20 whereas triglyceride (TG) levels appear 
higher18, 21 or unchanged.19 Low21, 22 or unchanged19, 20 levels of high-density 
lipoprotein cholesterol (HDL-C) were also found, as well as the presence of 
small and/or dense low-density lipoprotein cholesterol (LDL-C).19, 22 
Acromegalic patients have lower visceral and subcutaneous fat mass and 
increased intermuscular fat mass, which may be related with insulin 
resistance in this disease. It is also associated with increased lean body 
mass.23, 24 
Some studies reveal disruption of coagulation and fibrinolytic system. 
Fibrinogen levels seem to be consistently higher,25-29 whereas plasminogen 
activator inhibitor-1 (PAI-1) is either elevated27 or unchanged28, 29 in 
acromegalic patients. There is some evidence of the presence of higher levels 
of antithrombin III (ATIII), lower levels of protein S and unchanged levels of 
protein C and coagulation factor VIII.26, 27 C-reactive protein, an acute phase 
reactant, is shown to be lower25, 28, 30 or unchanged26 in acromegaly. 
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 Studies report amelioration of cardiac function and some cardiac risk 
factors with complete or partial biochemical control of acromegaly.28, 31-34 
There seems to be a decrease in blood pressure (BP) with control of the 
disease.11, 28, 31, 33, 34 However, changes in metabolic parameters are not well 
established. Some studies show increase in insulin sensitivity and better 
glucose regulation,28, 32, 34 while others show no modification in majority of 
patients.30, 35 As to lipidic profile, some studies can’t find any difference 
between active and controlled patients,30 while others report increase in HDL-
C and decrease in TC, LDL-C and TG.22, 28 Levels of fibrinogen were found to 
be either similar25, 26 or reduced28, 29 and levels of CRP were found to be 
either similar26 or increased28 after control of acromegaly. There is some 
evidence of decrease in PAI-128 and maintenance of Factor VIII levels.26 
As discussed above, there are no certainties about the changes in 
cardiovascular risk factors with control of acromegaly. Also, there are few 
studies approaching some risk factors, specially coagulation status. The aim 
of this study is to compare the presence of cardiovascular risk factors 
between acromegalic patients and a control population (non-functioning 
pituitary adenomas) and to evaluate the changes in these factors with control 
of the disease. Body mass index (BMI), blood glucose, BP, TC, HDL-C, LDL-
C and TG will be compared among each group. Protein S, Protein C, 
Antithrombin III, Factor VIII, Fibrinogen and genetics of PAI-1 will also be 
evaluated and compared. 
 
Subjects and Methods 
This study was approved by the Ethical Committee for Health of Hospital 
de São João (HSJ). It was a case-control study, performed in patients 
selected from the Endocrinology department of HSJ database. All patients 
included signed an informed consent form. 
 
Subjects 
Subjects were selected from Endocrinology department database. Patients 
who had died, whose follow up was lost or had the last surgery more than 10 
years ago, were excluded. Patients without data available on computer 
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internal network and without laboratory analysis made in the previous year 
were also excluded. Selected subjects were summoned by telephone call and 
those who refused, couldn’t come to the hospital or didn´t answer were also 
excluded from the study.  
This study included 23 acromegalic patients (table 1), 11 (5 men/6 women) 
with active disease and 12 (4 men/8 women) with controlled disease. Mean 
age was 50.64±12.63 in active group and 54.00±12.57 in controlled disease 
group. In both groups, most patients had macroadenomas at diagnosis. In 
active disease group, there were 3 newly diagnosed patients, who didn´t 
make any kind of treatment to the date of study. All other patients in this group 
underwent previous surgery and had necessity of medical therapy after that. 
Among controlled patients, only one was treated with radiotherapy and 
medical treatment. All other patients had previous surgery, 6 of them not 
having the need for medical therapy. 
Eleven controls (6 men/ 5 women) with non-functioning pituitary adenomas 
were evaluated. They were diagnosed with non-functioning adenoma, which 
has no hormonal hypersecretion. Elevated urinary free cortisol or cortisol after 
suppression test with dexamethasone, hyperprolactinemia, elevated thyroxine 
with high levels of thyroid-stimulating hormone or hypersecretion of GH were 
not proven. Diagnosis was confirmed with histological analysis after surgical 
resection. Mean age in this group was 51.36±13.76.  
 
Study Protocol 
Disease status was evaluated by IGF-1 levels and GH suppression after 
OGTT, when appropriate. Active disease was defined as IGF-1 levels over 
sex and age adjusted normal range or GH after OGTT over 1 µg/L. IGF-1 is 
expressed as percentage of upper limit of normal range (ULN). 
Anthropometric characteristics (height and body mass) were obtained from 
the last consultation register and body mass index (BMI) was calculated (body 
mass/height2). Blood pressure was also obtained from the same consultation 
and was measured by blood pressure monitor.  
Last available laboratory analysis of each patient were consulted and blood 
levels of glucose, total cholesterol (TC), low-density lipoprotein cholesterol 
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(LDL-C), high-density lipoprotein cholesterol (HLD-C) and triglycerides (TG) 
were collected. 
To evaluate coagulation status of included patients, blood samples were 
taken and levels of fibrinogen, protein S, protein C, AT III and coagulation 
factor VIII were measured. An evaluation of plasminogen activator inhibitor 1 
(PAI-1) genetic polymorphisms was also made. 
For statistical purposes, besides levels measured alone, patients were also 
categorized as having or not hypertension, hyperglycemia and hyperlipidemia. 
Hypertension was defined as SBP!140 and/or DBP!90, or being medicated 
for hypertension. Hyperglycemia was defined as having fasting glucose over 
110 mg/dL or being medicated for diabetes mellitus. Hyperlipidemia was 
defined as having hypercholesterolemia and/or hypertriglyceridemia (TC>200; 
LDL-C>130; HDL-C<60; TG>150). 
 
Laboratory Analysis  
Blood samples from acromegalic patients and controls were taken by 
venopunctures. Fibrinogen was measured by Clauss Method and AT-III, 
Protein C and Protein S were measured by functional methods, using 
reagents obtained from Diagnostica Stago (Asnieres-sur-Seine, France). 
Factor VIII levels were measured by coagulometric methods (Siemens 
Healthcare Diagnostics, Newark, Germany). 
For 4G/5G PAI-1 gene polymorphisms, DNA was extracted using QIAamp 
(Hilden, Germany) and real-time polymerase chain reaction (PCR) using 
LightCycler (Roche Molecular Biochemicals, Mannheim, Germany) was 
performed. A hybridization probes technique  (sequence-specific fluorescent 
detection with oligonucleotide hybridization probes that are coupled to suitable 
fluorophores) was applied. A mix with 2 µl genomic DNA (100 ng), 10.8 µl 
H2O, 1.6 µl MgCl2 (3 mM), 1 µl of each primer (10 µmol), 0.8 µl of each probe 
(5 µmol) and 2µl DNA-Master hybridization probes was used. Oligonucleotide 
primers and probes were synthesized by TIB MOLBIOL (Berlin, Germany) 
and cycling conditions involved initial denaturation (958°C for 600 s), followed 
by 45 cycles with denaturation at 958°C for 0 s, hybridization at 598°C for 5 s 
and extension at 728°C for 2s. Melting curves were obtained by slowly 
heating the sample to 758°C. Melting points of the two alleles were at 598°C 
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and 658°C. For better differentiation of heterozygotes, amplified products 
were run on agarose gel.36 
Serum glucose, TC, LDL-C, HLD-C and TG were measured by 
conventional methods with an Olympus AU5400! automated clinical chemistry 
analyzer. (Beckman-Coulter!, Izasa, Porto, Portugal). IGF-1 was measured by 
solid phase, enzyme labelled chemiluminescent immunometric assay and GH 
by solid phase, two-site chemiluminescent immunometric assay (Immulite 
2000®). 
 
Statistics 
Statistical analysis was made in Statistical Package for Social Sciences 
(SPSS). Values were tested for normality distribution by Kolmogorov-Smirnov 
and Shapiro-Wilk tests and log-transformed to achieve normal distribution 
when necessary. Parametric unpaired t-test was used to compare the groups. 
Spearman Rank Order Correlation coefficient was used to look for association 
between levels of IGF-1 or GH and variables in study. Pearson’s correlation 
was used to search association among the variables studied. In order to find if 
there was association between being in a group and having hypertension, 
hyperglycemia or hyperlipidemia, Chi-square test was used. P values under 
0.05 were considered significant. 
 
Results 
Table 2 summarizes comparison (GH, IGF-1 levels, %ULN, BMI, BP, lipidic 
profile and glucose status) among the three evaluated groups. Patients with 
active disease, as expected, had significantly higher levels of GH and IGF-1 
than controlled ones.  
BMI and levels of SBP and DBP were not significantly different among the 
three groups, although they were slightly higher in acromegalic patients. 
Active group had the highest mean blood pressures, and controlled group the 
highest levels of BMI. However, DBP was lowest in controlled acromegaly 
group. 
TC was slightly higher in active patients than controls, but the result was 
not statistically significant. When compared with controlled patients, the 
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difference was significant, with the active group having higher levels. HDL-C 
was higher in acromegalic patients, being significantly different between 
controlled patients and controls. In what concerns LDL-C, it was significantly 
lower in controlled patients when compared with active acromegalic ones. 
Levels were slightly higher in active patients than controls. Triglycerides were 
not significantly different among the three groups, being slightly higher in 
control group. 
Blood glucose was significantly higher in controlled acromegaly group and 
higher with borderline significance in active acromegaly group, when 
compared separately with control group. No difference was found between 
active and controlled acromegaly groups (although somewhat higher in active 
group).  
When categorizing patients as having hyperglycemia, hypertension and 
hyperlipidemia (table 3), higher percentages of all three variables were found 
in acromegalic patients when compared with controls. Hypertension 
prevalence was higher in controlled acromegalic group. Hyperglycemia and 
hyperlipidemia had the higher percentages in active disease group. However, 
significant correlation between those categories and the three studied groups 
was found only in hyperglycemia (p=0.002). 
Coagulation status of the three evaluated groups is summarized on table 4. 
Levels of protein C and S were similar among the groups. As to fibrinogen 
levels, these were significantly higher in acromegalic groups when compared 
with control group. There were no significant differences in these values 
between active and controlled patients (controlled patients having slightly 
higher levels). ATIII was significantly higher in active acromegaly when 
compared with control group and when compared with controlled acromegaly. 
There was no difference between control and controlled acromegaly groups. 
Although levels of coagulation factor VIII were slightly higher in controls than 
controlled acromegalic patients and in controlled acromegalic than active 
acromegalic patients, these values were not significantly different. 
When considering all acromegalic patients, significant positive correlation 
was found between ATIII and IGF-1 levels (r=0.654; P=0.001) and ATIII and 
GH levels (r=0.498; P=0.013). Dividing acromegalic patients in active and 
controlled groups, negative correlation was found between TC and GH in the 
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active group (r=-0.675, P=0.032) and positive correlation was found between 
LDL-C and IGF-1 levels in controlled disease group (r=0.630, P=0.038). 
Within the active acromegaly group, a negative correlation was found 
between GH and fibrinogen levels (r=-0.610; P= 0.046). 
A positive, significant correlation was found between glucose levels and 
BMI (r=0.478;P=0.005) and glucose and SBP (r=0.428; P=0.013). There was 
also found positive significant correlation between TC and LDL-C, TC and 
DBP, HDL-C and TG, LDL-C and DBP, SBP and DBP, BMI and SBP, protein 
C and DBP, protein C and HDL-C, coagulation factor VIII and fibrinogen. 
No correlation was found between hypopituitarism and the variables 
studied. 
Genetic polymorphisms of PAI-1 were evaluated. In control group, 54.5% 
were heterozygotes, 27.3% homozygotes by deletion and 18.2% 
homozygotes by insertion. Within active acromegaly group, 36.4% were 
heterozygotes, 18.2% homozygotes by deletion and 36.4% homozygotes by 
insertion (genetic polymorphism was not available for one patient). In 
controlled acromegaly group, 58.3% were heterozygotes, 25.0% 
homozygotes by deletion and 16.7% homozygotes by insertion. No 
differences among the groups were found. 
 
Discussion 
Since patients with non-functioning pituitary adenoma have no hormones 
production, these were used as control subjects. 
In this study, prevalence of hypertension in both acromegalic groups was 
within the range found in other studies (18 to 60%).6, 9-12 Although not 
significant, BP levels and prevalence of hypertension were slightly higher in 
acromegalic groups than in control group, results previously found in other 
studies.10 When comparing active and controlled acromegalic patients, BP 
levels seem to be slightly lower in controlled group, but hypertension prevails 
over active group. This happens probably because a higher percentage of 
patients in controlled group were taking anti-hypertensive medication. The 
tendency to slightly lower levels of BP in controlled acromegalic patients is in 
concordance with other studies, that show higher levels in active disease than 
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in controlled disease.28, 31, 33, 34 One study shows lower frequency of 
hypertension in active than in controlled acromegalic patients.11 As in other 
studies, no correlation was found between IGF-1 and GH levels and BP.10, 17, 
33 Fedrizzi et al. found no correlation among these values when including all 
acromegalic patients (active and controlled), but found correlation between 
SBP and IGF-1 levels in active acromegalic patients.11 
BMI was reported as being higher in acromegalic patients than controls in 
several studies.25, 37, 38 In the present study, no significant difference was 
found in BMI, with a slight tendency for controlled patients to have higher 
values, results that are in agreement with other studies.32, 39 However, there is 
evidence that acromegalic patients have different body composition: lower 
visceral and subcutaneous fat mass and increased intermuscular fat mass, 
with an increase in lean body mass and body water.23, 24 These changes 
probably make BMI less indicated when trying to deduce body composition or 
obesity presence in these patients, suggesting other measurements should be 
used. 
Prevalence of Diabetes Mellitus has been reported as being higher among 
acromegalic patients than in general population.15, 16 Higher insulin resistance 
and higher glucose and insulin levels in acromegalic patients compared with 
healthy subjects were also reported.26, 38 Findings in this study show 
significantly higher levels of fasting glucose and prevalence of hyperglycemia 
in all acromegalic patients when compared with control subjects. Although 
there seems to be a tendency for controlled acromegalic patients to have 
lower levels of fasting glucose, this difference is not statistically significant. 
Studies show different results after treatment of acromegaly: some report 
increase in insulin sensitivity and amelioration of glucose regulation;28, 32, 34 
others show no modification in glucose, insulin and insulin resistance.30, 35 
The results here reported suggest that there is an improvement in fasting 
glucose in controlled patients, but with glucose status remaining worse than in 
control subjects, which should be taken in account when evaluating 
acromegalic patients, even when having disease control. A significant 
correlation between fasting glucose levels and SBP was found, an association 
also previously established.15, 17 
! *"!
Comparing lipidic values between control and active acromegaly groups, 
there appears to be higher TC and LDL-C, similar HDL-C and lower TG levels 
and higher hyperlipidemia prevalence. Yet, these values are not statistically 
significant. Other authors have found TC levels to be similar, HDL-C lower or 
unchanged and TG higher or unchanged when compared with a control 
population18-22. Results regarding LDL-C appear to report either similar or 
higher levels in acromegalic patients;19, 20, 22 in these studies, higher levels of 
small and/or dense LDL-C were consistently reported.19, 22 Controlled 
acromegalic patients appear to have a better lipidic profile with significant 
lower levels of TC and LDL-C than active patients. When compared with 
control population, there seems to be a better lipidic profile with significant 
higher levels of HDL-C. However, there is a higher percentage of 
hyperlipidemic controlled patients, because more of them were under anti-
dyslipidemic medication. This suggests close attention and control of 
dyslipidemia in acromegalic controlled patients is effective and probably 
addictive to control of the disease. Studies reported increase in HDL-C and 
decrease in TC, LDL-C and TG with control of the disease, supporting the 
present findings.22, 28 
Within active acromegaly group, there seems to be a significant negative 
correlation between GH and TC levels. When considering controlled 
acromegaly group there is a positive association between IGF-1 and LDL-C 
levels. Maison et al. suggest different effects of GH and IGF-1 on lipidic 
profile.40 One study reports that administration of GH antagonist in 
acromegaly increase TC41 and another that GH is responsible for lowering 
LDL-C by accelerating its elimination rate.42 Szkodziñski et al, report that 
administration of statins and low fat diet in hypercholesterolemic patients 
reduce IGF-1, TC and LDL-C.43 
Different studies find elevated levels of fibrinogen in acromegalic patients, 
with decrease of those levels after treatment.25-29 Residual risk with higher 
levels in treated patients than controls was found in some studies.25, 28, 29 In 
the present study, higher levels of fibrinogen were also found in both active 
and controlled acromegaly groups when compared with control group. No 
differences were found between active and controlled group. Few studies 
evaluate the role of protein C, protein S and ATIII in acromegaly. Erem et al 
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showed higher levels of ATIII, lower levels of protein S and no difference in 
protein C levels between acromegalic patients and a control population27. In 
this study, higher levels of ATIII were found in active acromegalic patients 
when compared with both control population and controlled patients, with no 
differences found between control and controlled acromegaly groups. Similar 
levels of proteins C and S were found among the three groups. Levels of 
coagulation factor VIII were similar in evaluated groups, as in other studies 
that found no significant difference in factor VIII levels between acromegalic 
patients and control subjects or between remission and active disease.26, 27 
High fibrinogen levels in acromegalic patients suggest the existence of a pro-
coagulation status in acromegaly, with residual risk in controlled disease. 
However, ATIII levels may be elevated in response to high fibrinogen, 
counterbalancing its effect. Coagulation status in acromegalic patients should 
be further studied. 
PAI-1 polymorphisms were no different among the three groups, which 
suggest no genetic predisposition for this factor is present in acromegalic 
patients. 
In conclusion, patients with active acromegaly have subtle changes in BP, 
and relevant changes in lipidic profile, glucose and coagulation status. With 
control of the disease, there is amelioration of these parameters, but probably 
with a residual risk superior to control subjects. Although trying to deduce 
cardiovascular risk, this study is not able to access morbidity and mortality risk 
in acromegalic patients. 
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Figure 1. Magnetic Resonance of a pituitary macroadenoma with suprasellar 
extension and mass effect over several cerebral structures. 
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Table 1. Clinical Characteristics of control subjects, patients with active acromegaly 
and controlled acromegaly. 
 
Parameter 
Controls 
Active 
Acromegaly 
Controlled 
Acromegaly 
Number of patients 11 11 12 
Sex (male/female) 6/5 5/6 4/8 
Age* 51.36 ± 13.76 50.64±12.63 54.00±12.57 
Disease duration __________ 3.91±3.05 7.42±8.16 
Macro/Microadenoma 11/0 9/2 11/1 
Previous surgery 
(yes/no) 
11/0 8/3 11/1 
Previous radiotherapy 
(yes/no) 
0/12 0/11 1/11 
Medical treatment 
(SMS analogs/GHR 
antagonists/No) 
__________ 6/2/3 6/0/6 
Hypopituitarism 
(yes/no) 
4/7 1/10 0/12 
Values are expressed as means ± Std. Deviation 
SMS analogs: somatostatin analogs; GHR antagonists: Growth Hormone Receptor 
antagonists  
* No statistically significant differences in age among groups 
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Table 2. GH and IGF-1 levels and %ULN in patients with acromegaly. BMI, BP, 
lipidic profile and glucose status in control, active acromegaly and controlled 
acromegaly groups. 
 
Parameter 
Controls 
Active 
Acromegaly 
Controlled 
Acromegaly 
P-value 
(a) (b) (c) 
GH (µg/L) ______ 11.57±10.80 1.25±1.34 ______ ______ 0.01 
IGF-1 
(µg/L) 
______ 612.00±373.22 230.33±70.17 ______ ______ 0.007 
%ULN ______ 250.42±134.61 95.75±14.88 ______ ______ 0.003 
BMI 
(Kg/m2) 
28.91±4.76 29.06±5.72 31.53±5.93 ns ns ns 
SBP 
(mmHg) 
126.55±23.31 133.45±19.59 129.25±15.98 ns ns ns 
DBP 
(mmHg) 
74.55±16.12 76.27±11.29 72.67±8.74 ns ns ns 
TC 
(mg/dL) 
188.55±41.25 201.73±34.57 170.42±31.67 ns ns <0.05 
HDL-C 
(mg/dL) 
47.36±6.48 46.55±11.46 56.08±12.51 ns <0.05 ns 
LDL-C 
(mg/dL) 
111.09±31.40 130.82±31.48 96,82±25,23ª ns ns 0.01 
TG 
(mg/dL) 
135.09±49.12 121.91±32.94 105.82±40.87ª ns ns ns 
Blood 
glucose 
(mg/dL) 
87.91±13.19 151.2±102.5 108.33±23.43 0.05 <0.05 ns 
Values are expressed as means ± Std. Deviation; ª No data available for 1 subject 
GH – Growth Horomone; IGF-1 - Insulin-like Growth Factor 1; %ULN - percentage of Upper 
Limit of Normal Range; BMI – Body Mass Index; SBP – Systolic Blood Pressure; DBP – 
Diastolic Blood Pressure; TC – Total Cholesterol; HDL-C – High Density Lipoprotein 
Cholesterol; LDL-C – Low Density Lipoprotein Cholesterol; TG – Triglycerides.  
(a) Controls vs Active Acromegaly; (b) Controls vs Controlled Acromegaly; (c) Active 
Acromegaly vs Controlled Acromegaly; ns: non significant. 
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Table 3. Hypertension, hyperglycemia and hyperlipidemia in studied groups. 
 
Category 
Control Active Acromegaly 
Controlled 
Acromegaly 
Hypertension 27.3% 36.4% 50% 
Hyperglycemia* 0% 72.7% 58.3% 
Hyperlipidemia 54.5% 81.8% 66.7% 
*P=0.001 
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Table 4. Coagulation status in control, active acromegaly and controlled acromegaly 
groups. 
 
Parameter 
Controls 
Active 
Acromegaly 
Controlled 
Acromegaly 
P-value 
(a) (b) (c) 
Fibrinogen 
(mg/dL) 
356±86 427±62 437±107 <0.05 <0.05 ns 
Protein C 
(U/mL) 
1.17±0.21 1.17±0.20 1.20±0.26 ns ns ns 
Protein S 
(U/mL) 
0.97±0.19 1.07±0.22ª 1.02±0.16 ns ns ns 
Antithrombin III 
(U/mL) 
0.95±0.16 1.13±0.09 1.02±0.16 <0.05 ns 0.05 
Factor VIII 
(%d.N.) 
134.90±33.45 120.08±32.61 129.32±45.42 ns ns ns 
(a) Controls vs Active Acromegaly; (b) Controls vs Controlled Acromegaly; (c) Active 
Acromegaly vs Controlled Acromegaly; ns: non significant.  
  ª No data available for 1 subject 
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Anexo II 
 
Normas de Publicação na revista Hormones  
INSTRUCTIONS FOR PREPARATION OF 
MANUSCRIPT 
  
HORMONES publishes articles related to: 
• Original research findings on humans or experimental animals 
• Complete reviews of the Literature 
• Case reports 
• Puzzling cases: Undiagnosed cases or cases in which the final 
diagnosis was unexpected 
• Editorial Comments 
• News and Views 
• Book Reviews 
• Letters to the Editor 
• Short notes on etymology of medical terms 
• History of Endocrinology 
PREPARATION OF MANUSCRIPT 
• Must be written in English 
• Use wide margins 
• Number all pages 
• Use separate pages for title page, references, footnotes, tables, 
legends 
The title page should include 
• Full title 
• Abbreviated title of not more than 40 characters 
• Authors' names and institution affiliations 
• Corresponding author's address, telephone number, fax and e-mail 
• Key words up to 8 
• Grants or fellowship supports 
ABSTRACT 
For research papers the abstracts must be structured: OBJECTIVE, 
DESIGN, RESULTS, CONCLUSIONS. Not exceeding 200 words (not 
necessary for review articles) 
Abstract is not necessary for review articles. Describe briefly the 
background, the aim of the study or the hypothesis tested, the methods 
used, the results and the conclusions. 
MAIN TEXT 
Follow the usual architectural model, namely: introduction, subjects or 
experimental animals and methodology, results, discussion   Laboratory 
values should be stated in both the international system (SI units) and in 
metric units in parenthesis. The abstract should be stated only in SI 
units. Temperatures should be written in degrees Celsius 
FOOTNOTES 
The text should be numbered consecutively at the foot of each page 
using a line for separation from the text 
FIGURES 
For electronic submission use a separate file for each figure in one of 
the three acceptable formats TIF, EPS, jPG (at least 300dpi). For mail 
submission send 3 sets of figures for the reviewers and 2 original sets 
for press requirements. Mark with a soft pencil only on the back the 
number of the figure, the name of the first author and the presentation 
(top) with an arrow. Number in Arabic numerals.  TABLES should be 
presented on separate plain pages as printed text. Tables require a 
concise heading. 
REFERENCES   References should be cited consecutively in numerical 
order in the text (as superscript outside the punctuation) and the same 
numerical order must be followed on a separate sheet at the end of the 
manuscript. The title of the Journals used follow the abbreviated style 
used in the index medicus. The author is responsible for the accuracy of 
references. 
Examples of References 
• Papers published in Journals: 
Mahagan T, Lightman SL, 2000 A simple test for growth hormone 
deficiency in adults. J Clin Endocrinol Metab 85: 1473-1476 
When the number of authors exceeds six, the designation et al must be 
used after the third author 
• Books 
Mazzaferri EL 1993 Thyroid carcinoma. Papillary and follicular. In: 
Mazzaferri EL, Samaan N (eds) Endocrine tumors, Blackwell Scientific 
Publications Inc, Cambridge; pp, 278-333 
SUBMISSION PROCEDURES 
• Electronic  Through our website www.hormones.gr  - Create an 
account as an author  - Log in to our system as an author  - 
Follow the on-line instructions step by step  - The home page also 
includes FAQs for any further information you may need. 
 Manuscripts may also be sent to: info@hormones.gr 
• Mail  Submission of an original and four copies, typewritten on one 
side, double spaced on standard paper. Manuscript accompanied 
by a disk with the text in electronic form. Please label the outside 
of the diskette with the first author’s name and the word 
processing program and version (e.g., Word-Perfect 5.0). 
 Provision of a statement signed by all authors that the 
manuscript has not been published or submitted elsewhere. 
Personal communications should not be included in the 
references. They may be cited in the text in parentheses. Papers 
in press may be mentioned in the references given the Journal. 
• Personal communications should not be included in the references. 
They may be cited in the text in parentheses. Papers in press 
may be mentioned in the references given in the Journal. 
Manuscripts will become the permanent property of HORMONES and 
should not be published elsewhere without written permission from the 
authors and Journal. 
Manuscripts are submitted to HORMONES with the understanding that 
they have not been simultaneously submitted to other journals 
ETHICAL CONSIDERATION 
Authors should state these, when applicable. The relevant statement 
should also be accompanied by a notation of approval by the 
institutional committee on human research, whenever applicable 
